ArticleBioscience reports2026
Kinetic, computational, and phylogenetic characterisation of PA2125 from Pseudomonas aeruginosa PAO1: a hydroxybenzaldehyde dehydrogenase of the newly defined ALDH33 family.
Article in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PA2125 from Pseudomonas aeruginosa PAO1 is annotated as an aldehyde dehydrogenase (ALDH), but its substrate specificity, catalytic properties, and phylogenetic family assignment had not been established. Here, we cloned the PA2125 gene, produced and purified the recombinant PA2125 protein, and combined extensive substrate screening and steady-state kinetic characterisation with molecular dockings, molecular dynamics simulations, and phylogenetic analysis. PA2125 preferred NAD+ over NADP+, and screening of 54 aldehydes revealed a narrow substrate range centred on substituted benzaldehydes, particularly hydroxybenzaldehydes. Gentisaldehyde (GSA; 2,5-dihydroxybenzaldehyde) was the preferred substrate, with a KM of 5.3 μM, a kcat of 192 s-1, and a remarkably high kcat/KM (3.54 × 107 M-1 s-1). 3-Hydroxybenzaldehyde and 3,5-dihydroxybenzaldehyde also showed low KM values but approximately sevenfold lower catalytic efficiencies. Initial-velocity patterns supported an ordered sequential steady-state Bi Bi mechanism in which NAD+ binds first. Whereas GSA showed no substrate inhibition at concentrations up to 45 × KM, the other two hydroxybenzaldehydes showed pronounced total substrate inhibition-likely due to aldehyde binding at the nucleotide-binding site-at concentrations close to their KM. Docking identified plausible interactions involving unusual active-site residues, whereas molecular dynamics simulations showed that GSA more frequently populated and more readily accessed catalytically competent geometries. Phylogenetic analyses defined a distinct bacterial ALDH family, here designated ALDH33, comprising three subfamilies, with PA2125 belonging to ALDH33A. Together, these results identify GSA as the preferred in vitro substrate of PA2125, support its biochemical assignment as a gentisaldehyde dehydrogenase, and provide a foundation for investigating its physiological role in aromatic-aldehyde metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.